Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumor, Adult
Interventions: BIOLOGICAL: EOC202|DRUG: Paclitaxel
Sponsor: Taizhou EOC Pharma Co., Ltd.